Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

KPV.

Research draft

KPV is a tripeptide corresponding to the terminal sequence of alpha-melanocyte-stimulating hormone.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

KPV is a tripeptide corresponding to the terminal sequence of alpha-melanocyte-stimulating hormone.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFO3 amino acids
PRIMARY CONTEXTAnti-inflammatory tripeptide

Mechanism

Experimental work examines inflammatory signalling and epithelial transport.

Human research

No therapeutic human evidence sufficient to establish benefit was identified in the regulatory assessment reviewed.

Preclinical & other research

Cell and animal studies investigated inflammatory and intestinal models, including targeted oral delivery.

Safety & unknowns

Human effects and long-term exposure risks remain uncertain.

Regulatory status

Research compound; neither animal benefit nor compounding discussion establishes approval.

Reported use & evidence

Research profile draft

The supplied KPV profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds